GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Net Change in Cash

Pfenex (Pfenex) Net Change in Cash : $19.42 Mil (TTM As of Jun. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Pfenex Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Pfenex's Net Change in Cash for the three months ended in Jun. 2020 was $-4.57 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2020 was $19.42 Mil.

Pfenex Net Change in Cash Historical Data

The historical data trend for Pfenex's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfenex Net Change in Cash Chart

Pfenex Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Change in Cash
Get a 7-Day Free Trial 60.44 -28.62 -23.64 -1.44 -0.60

Pfenex Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.13 -9.10 23.11 9.98 -4.57

Pfenex Net Change in Cash Calculation

Pfenex's Net Change in Cash for the fiscal year that ended in Dec. 2019 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.128+-0.845+4.377+0
=-0.60

Pfenex's Net Change in Cash for the quarter that ended in Jun. 2020

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-5.326+0.187+0.573+0
=-4.57

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfenex Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Pfenex's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfenex (Pfenex) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Net Change in Cash
Comparable Companies
AVXL GRTS KLDO AFMD NYMX NWBO MNOV FBIO XCUR XOMA OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
10790 Roselle Street, San Diego, CA, USA, 92121
Website
https://www.pfenex.com
Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.
Executives
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Jason Grenfell-gardner director 105 LINCOLN AVENUE BUENA NJ 08310
Patrick K. Lucy officer: Chief Business Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Robin Campbell director C/O PFENEX INC., 10790 ROSELLE STREET SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Mack Taylor director C/O PFENEX, INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Evert B. Schimmelpennink director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Shawn Scranton officer: Chief Operating Officer C/O PFENEX INC 10790 ROSELLE STREET SAN DIEGO CA 92121
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Lorianne Masuoka director C/O PFENEX INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Newtyn Management, Llc 10 percent owner 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116

Pfenex (Pfenex) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - MJCO, PFNX, MXIM, GRUB

By PRNewswire PRNewswire • 09-10-2020

Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D.

By Marketwired Marketwired • 03-04-2019

Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)

By Marketwired Marketwired • 07-12-2018

Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW

By Marketwired Marketwired • 02-28-2019

Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer

By Marketwired Marketwired • 03-18-2019

SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm - NGHC, PFNX, MXIM, INWK

By PRNewswire PRNewswire • 08-22-2020

Pfenex Set to Join Russell 2000® Index

By Marketwired Marketwired • 06-23-2018

WeissLaw LLP Reminds PFNX and PRNB Shareholders About Its Ongoing Investigations

By PRNewswire PRNewswire • 09-02-2020

Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Sprin

By PRNewswire PRNewswire • 09-11-2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfenex Inc. - PFNX

By Marketwired Marketwired • 06-04-2020